New Alzheimer's pill targets brain disease markers in blood
NCT ID NCT07236190
Summary
This early-stage study aims to see if a pill called NPC-1 (containing parthenolide and ipriflavone) is safe and can change certain markers of Alzheimer's disease in the blood over six months. It will involve 40 adults aged 55+ who have early memory concerns or mild Alzheimer's and show signs of the disease in blood or brain scans. The main goal is to check if the treatment affects these biological signs and is well-tolerated, not to improve memory symptoms directly.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Massachusetts General Hospital
Boston, Massachusetts, 02129, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.